DEFA14A: OptiNose and Paratek Merger: Employee FAQs Address Key Transition Concerns

OptiNose addresses employee concerns regarding pay, benefits, and job security following the pending merger with Paratek Pharmaceuticals.

Summary

• OptiNose has released a communication addressing frequently asked questions from employees regarding the pending merger with Paratek Pharmaceuticals.
• The communication assures employees that business operations and team member roles will remain largely the same in the short term, with a focus on maintaining stability and continuity.
• There will be no immediate changes to pay, and employees will receive comparable base salary, wage rate, and target annual bonus opportunities for 12 months post-closing.
• OptiNose health benefits and programs will remain in place until December 31, 2025, after which Paratek will provide comparable benefits.
• The OptiNose 401(k) plan will remain in effect until the end of December 2025 and is expected to merge with the Paratek 401(k) plan for 2026.
• Employees will continue to be paid using the OptiNose payroll system until the end of December 2025, transitioning to the Paratek payroll process in 2026.
• Outstanding commitments made in OptiNose offer letters, such as sign-on bonuses, will be honored by Paratek.
• If an OptiNose employee is terminated without cause within 12 months of closing, they will be entitled to severance payments and benefits under the OptiNose Colleague Severance Change in Control and Severance Benefit Plan.
• Paratek has agreed to honor OptiNose service dates for eligibility, vesting, and benefit determination.

Sentiment

Score: 7

Explanation: The document aims to reassure employees during a period of uncertainty, indicating a moderately positive sentiment. However, the inclusion of risk factors and potential changes tempers the overall optimism.

Positives

• Short-term stability is assured for OptiNose employees regarding their roles and responsibilities.
• Pay and benefits will remain comparable for at least 12 months after the merger.
• Existing commitments, such as sign-on bonuses, will be honored.
• Severance benefits are in place for employees terminated without cause within 12 months of the merger.
• Service credit with OptiNose will be honored by Paratek for benefit eligibility and vesting.

Negatives

• There will be changes to benefits and payroll systems in 2026, requiring employees to adapt to new processes.
• The document contains forward-looking statements that are subject to risks and uncertainties, including the risk that the merger may not be completed.

Risks

• The proposed transaction may not be completed in a timely manner or at all, which may adversely affect the company's business and stock price.
• Failure to obtain necessary regulatory approvals or stockholder approval could prevent the merger.
• Disruptions from the pending merger may make it more difficult to maintain business and operational relationships.
• The merger could divert management's attention from ongoing business operations.
• The merger could result in negative effects on the market price of the company's common stock and operating results.
• Significant transaction costs and unknown liabilities could arise.
• Litigation, including shareholder litigation, and/or regulatory actions could occur.

Future Outlook

The document outlines the expected integration process following the merger, including harmonization of benefits, payroll, and other policies in 2026. It also includes forward-looking statements about the completion and timing of the proposed transaction, which are subject to risks and uncertainties.

Industry Context

Mergers and acquisitions are common in the pharmaceutical industry as companies seek to expand their product portfolios, reduce costs, and gain access to new technologies. This merger reflects a trend towards consolidation in the sector.

Stakeholder Impact

• Shareholders are impacted by the potential risks and benefits of the merger, as outlined in the forward-looking statements.
• Employees are directly impacted by changes to their roles, pay, benefits, and working conditions.
• Customers, vendors, service providers, independent sales representatives, agents, and agencies may experience disruptions due to the merger.

Next Steps

• Formal integration activities will commence following the close of the merger and continue over the next several months.
• Department leaders will provide more information to their respective teams regarding any changes to reporting relationships.
• Open enrollment for the new calendar year's benefits plan at Paratek will occur in Q4, 2025.
• Further information about digital access and equipment will be provided as the integration process moves forward.
• Additional information on incentive opportunities will be provided as part of the integration process.
• Expense reimbursement processes will be harmonized as part of the integration activities.
• Cell phone reimbursement policies and processes will be harmonized as part of the integration activities.
• Further information about Paratek's tuition reimbursement program will be provided as integration activities continue.
• Additional information about life insurance and disability insurance coverages will be provided as the integration activities continue.

Key Dates

Keywords

merger, OptiNose, Paratek, employees, benefits, payroll, severance, integration, acquisition